Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,485
  • Shares Outstanding, K 1,034
  • Annual Sales, $ 1,920 K
  • Annual Income, $ -31,540 K
  • 60-Month Beta 1.14
  • Price/Sales 7.13
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AVTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -140.48
  • Growth Rate Est. (year over year) +99.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.98 +30.66%
on 06/10/24
14.00 -6.86%
on 06/21/24
+2.12 (+19.41%)
since 05/21/24
3-Month
4.60 +183.48%
on 03/27/24
34.46 -62.16%
on 03/28/24
+8.44 (+183.48%)
since 03/21/24
52-Week
3.95 +230.12%
on 01/17/24
1,130.40 -98.85%
on 06/23/23
-946.96 (-98.64%)
since 06/21/23

Most Recent Stories

More News
Origin Materials and Avantium to Accelerate the Mass Production of FDCA and PEF for Advanced Chemicals and Plastics

Origin Materials, Inc. (“Origin” and “Origin Materials”) (NASDAQ: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable...

ORGN : 0.9000 (-6.12%)
ORGNW : 0.0401 (-8.66%)
AVTX : 13.04 (-1.66%)
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate $15 million of upfront payment received...

AVTX : 13.04 (-1.66%)
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Topline Pivotal trial results expected 1H2023...

AVTX : 13.04 (-1.66%)
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments.Apollo to lead continued clinical development of...

AVTX : 13.04 (-1.66%)
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split

WAYNE, Pa. and ROCKVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a one-for-twelve reverse stock...

AVTX : 13.04 (-1.66%)
Avalo to Present at the 2022 Jefferies Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D.,...

AVTX : 13.04 (-1.66%)
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)

Topline results expected 4Q2022...

AVTX : 13.04 (-1.66%)
Avalo to Present at the H.C. Wainwright Global Life Sciences Conference

WAYNE, Pa. and ROCKVILLE, Md., May 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D.,...

AVTX : 13.04 (-1.66%)
Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates

Reaffirms milestone timing for Phase 2 clinical trial of AVTX-002 in non-eosinophilic asthma (NEA) and pivotal trial of AVTX-803 in leukocyte adhesion...

AVTX : 13.04 (-1.66%)
Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine...

AVTX : 13.04 (-1.66%)

Business Summary

Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is...

See More

Key Turning Points

3rd Resistance Point 15.13
2nd Resistance Point 14.57
1st Resistance Point 13.80
Last Price 13.04
1st Support Level 12.47
2nd Support Level 11.91
3rd Support Level 11.14

See More

52-Week High 1,130.40
Fibonacci 61.8% 700.10
Fibonacci 50% 567.18
Fibonacci 38.2% 434.25
Last Price 13.04
52-Week Low 3.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar